Voyager CEO Al Sandrock outlines a focused strategy: remain specialists in neurology, but broaden the therapeutic modalities (gene therapy, proteins, oligonucleotides). This allows them to pursue well-validated CNS targets that are considered "undruggable" by traditional small molecules, which have historically been the only option for crossing the blood-brain barrier.

Diakonos' personalized therapy piggybacks on the existing patient journey. The required tumor sample is collected during the standard-of-care surgery that glioblastoma patients already undergo. This integration minimizes patient burden and simplifies logistical hurdles for clinical adoption.

By treating patients before their tumors are surgically removed, Infinitopes can analyze the resected tissue. This provides direct evidence of CD8 T cell infiltration in response to the vaccine—a powerful, mechanistic proof-point that is impossible for competitors testing in later-stage patients.

Recognizing that severe myotonic dystrophy involves CNS impairment, Arthex deliberately invested in a lipid conjugation delivery system for its RNA therapeutic. This strategic choice was made specifically to cross the blood-brain barrier, enabling the treatment of both muscular and neurological symptoms of the disease.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.

Glioblastoma evolves under therapeutic pressure, changing its expression and metabolism to resist treatment. Adaptin Bio's platform is designed to be adaptive, allowing them to switch therapeutic payloads (e.g., from APTN-101 to 102) as the tumor changes, effectively staying one step ahead.

Diakonos chose glioblastoma, the deadliest brain cancer, for its first trial. This counterintuitive strategy provided a faster data readout, powerful validation upon success, and a lower regulatory burden from the FDA—all critical advantages for an early-stage company.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.